Psychedelics: A New Treatment Paradigm in Psychiatry?

The renaissance of psychedelics has accelerated further over the past year. At least that’s true if you follow the public press. The New York Times recently titled “The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.” on its front page [1].

Publication History

Received: 25 May 2021
Received: 25 May 2021

Accepted: 26 May 2021

Article published online:
24 June 2021

• References

• 1 The New York Times. The psychedelic revolution is coming. Psychiatry may never be the same. 2021; https://www.nytimes.com/2021/05/09/health/psychedelics-mdma-psilocybin-molly-mental-health.html (accessed on May 21^st, 2021)
• 2 Mitchell JM, Bogenschutz M, Lilienstein A. et al. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021
• 3 Carhart-Harris R, Giribaldi B, Watts R. et al. trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402-1411
• 4 Yaden DB, Yaden ME, Griffiths RR. psychedelics in psychiatry-keeping the renaissance from going off the rails. J Am Med Assoc Psychiatry 2021; 78: 469-470
• 5 Nichols DE, Walter H. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2021; 54: 151-166
• 6 Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry. 2021; 54: 167-175
• 7 Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry—current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry. 2021; 54: 176-190
• 8 Gründer G, Jungaberle H. The potential role of psychedelic drugs in mental health care of the future. Pharmacopsychiatry. 2021; 54: 191-199